PT-141 (Bremelanotide) + MOTS-c Stack: Safety and Monitoring Guide

What each peptide is

Bremelanotide is a cyclic peptide of 7 amino acids and a melanocortin receptor agonist. It activates MC1R, MC4R, MC3R, MC5R and MC2R in that order of potency, with MC1R and MC4R binding most relevant at the approved dose, and how it improves sexual desire is unknown [1]. Vyleesi, the approved product, is a 1.75 mg subcutaneous autoinjector used as needed at least 45 minutes before sexual activity, no more than once in 24 hours and no more than 8 doses a month, self-injected into the abdomen or thigh [1]. It is indicated only for premenopausal women with acquired, generalized HSDD and is not indicated for men, for postmenopausal women, or to enhance sexual performance [1]. After a dose, median time to peak blood concentration is about 1 hour and the mean terminal half-life is about 2.7 hours [1].

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 [5]. It is not part of any approved drug, and FDA treats the free base and the acetate salt as different bulk substances [2]. In human blood in the laboratory it breaks down quickly, which FDA noted raises the question of whether injecting it can produce active levels in a person [2].

Bremelanotide acts on melanocortin receptors. For MOTS-c, rodent and cell experiments point to AMPK signaling and reduced one-carbon folate metabolism, though FDA says its molecular targets are unknown [1][2][5].

What the Vyleesi label says to watch

Blood pressure and heart rate

The label's central safety issue is a transient rise in blood pressure and fall in heart rate with every dose. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after dosing, with a heart rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours, and repeat daily dosing 24 hours apart for up to 16 days produced no additive effect [1]. Those are maximal figures. In a separate open-label ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1].

Nausea

Nausea was reported by 40% of Vyleesi-treated women versus 1.3% on placebo, 13% needed an anti-nausea medicine, and 8% stopped the trials because of it [1]. Median onset was within an hour of the dose and it lasted about two hours; it was highest after the first dose (21% of patients) and declined to about 3% with later doses [1]. Pre-treating with 8 mg oral ondansetron 30 minutes before the injection did not reduce nausea in a 228-woman phase 4 study, and the label says this pre-treatment is not recommended [1]. For persistent or severe nausea, the label says to consider discontinuing Vyleesi, or starting an anti-emetic for patients who are bothered by nausea but wish to continue [1].

Skin darkening

Focal hyperpigmentation, including darkening of the face, gums or breasts, was reported by 1% of patients using up to 8 doses a month in the placebo-controlled trials and by no placebo patients [1]. The label notes a higher risk with daily dosing: in another study, 38% of patients developed focal hyperpigmentation after 8 consecutive days of daily dosing, and an additional 14% after 8 more days [1]. Patients with darker skin were more likely to develop it, and resolution was not confirmed in all patients after the drug was stopped [1]. The label says to consider discontinuing Vyleesi if hyperpigmentation develops [1].

Other label signals

Serious adverse reactions occurred in 1.1% of Vyleesi-treated patients versus 0.5% on placebo, and 18% stopped treatment because of adverse reactions versus 2% on placebo [1]. One case of acute hepatitis appeared in the open-label extension after 10 doses over a year, with transaminases more than 40 times the upper limit of normal; liver tests returned to normal 4 months after the drug was stopped, and a role for Vyleesi could not be definitively excluded [1].

The label also states that Vyleesi may slow stomach emptying and reduce absorption of oral medicines; it says to avoid Vyleesi with oral drugs that depend on threshold blood concentrations, such as antibiotics, and with oral naltrexone products intended to treat alcohol or opioid addiction [1]. Exposure rises 1.5-fold in moderate and 2-fold in severe renal impairment, and the label advises caution in patients with an eGFR <30 mL/min/1.73 m2, who may have more frequent or severe adverse reactions such as nausea and vomiting [1]. The label advises females of reproductive potential to use effective contraception and to discontinue Vyleesi if pregnancy is suspected; in dogs, fetal harm occurred at exposures at least 16 times the human dose by AUC [1]. FDA approved a labeling supplement on October 22, 2026 that updates the pregnancy and specific-populations section, and that new text was not yet in DailyMed on October 28, 2026 [1].

MOTS-c: what is known about safety

FDA found no published study in which MOTS-c, compounded or not, was given to a human, so no human dose, safety profile, pharmacokinetic data or MOTS-c-specific monitoring target is established [2]. FDA's adverse-event database search through March 9, 2025 returned no reports naming MOTS-c, and its stated concern for the injectable form is immunogenicity, an immune reaction to peptide aggregates and impurities; there are no immunogenicity data for the peptide [2].

MOTS-c effects on metabolism come from mice and cells. Human studies measured the body's own MOTS-c after exercise; they did not test injected MOTS-c [6][7]. In mice on a high-fat diet, MOTS-c at 0.5 mg/kg/day intraperitoneally was associated with about 20% lower body weight after 8 weeks [2][5]. In another mouse study, a late-life schedule of 15 mg/kg three times weekly, started at 23.5 months of age, lengthened median lifespan from 912 to 970 days [2]. Those doses cannot be converted into a human dose, and FDA says no dose-response relationships were assessed [2]. The uses nominated for compounding were insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity, as 5 mg and 10 mg subcutaneous injections [2].

Monitoring

The only monitoring guidance comes from the Vyleesi label: consider cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment [1]. For MOTS-c, no monitoring target is established because there are no human data [2].

Where each half stands legally

Vyleesi was approved on June 21, 2019 under NDA 210557 and carries no boxed warning [1][8]. PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [4][1]. Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks, and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [9][10][11].

MOTS-c is not an approved drug [2]. FDA staff proposed in July 2026 that neither MOTS-c free base nor acetate be added to the pharmacy bulk substances list, and the Pharmacy Compounding Advisory Committee voted the other way on July 23, 2026 in a vote that is advice only and not binding; adding the substance would take formal rulemaking [2][12][4]. HHS's draft policy, filed October 28, 2026, names MOTS-c among six peptides and says the department does not intend to take enforcement action against certain licensed pharmacies and physicians compounding MOTS-c acetate for subcutaneous or intramuscular injection if its conditions are met; the notice states that it is not binding, establishes no rights, and is not an approval [4][11]. For athletes, WADA names MOTS-c in section S4.4.1 as an AMPK activator and prohibits it at all times, in and out of competition [3]. Bremelanotide is not named on WADA's 2026 or 2027 Prohibited Lists [3][13].